This site is intended only for healthcare professionals resident in the Republic of Ireland
Menu
Close
Menu
Close
Click here for CIBINQO Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
JADE Clinical Program Overview
Efficacy Overview
Key endpoints and objectives studied in clinical trials:
Studied CIBINQO vs placebo as monotherapy in 654 adult patients2,3
Studied CIBINQO vs placebo and vs dupilumab as a combination therapy with TCS in 837 adult patients1
Studied CIBINQO as monotherapy in 987 adults and 246 adolescents aged ≥12 years (N=1233)4
Responders* (n=798) were identified after 12-week OL treatment with CIBINQO 200 mg and randomised to CIBINQO 200 mg, CIBINQO 100 mg, or placebo during a 40-week maintenance period to assess:
An ongoing long-term extension safety and efficacy study evaluating CIBINQO +/- TCS in adults and adolescents aged ≥12 years8,9
An ongoing long-term extension safety and efficacy study evaluating CIBINQO +/- TCS in adults and adolescents aged ≥12 years7,8
Head-to-head clinical trial studied CIBINQO 200 mg vs dupilumab as a combination therapy with TCS in 727 adult patients6
Head-to-head clinical trial studied CIBINQO 200 mg vs dupilumab as a combination therapy with TCS in 727 patients aged ≥18 years6
Although some clinical trials included adolescents, please note that CIBINQO is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.
AD=atopic dermatitis; EASI=Eczema Area and Severity Index; IGA=Investigator’s Global Assessment; PP-NRS=Peak Pruritus Numerical Rating Scale; OL=open-label.
Prescribing information
Please see the CIBINQO Summary of Product Characteristics for more information.
CIBINQO is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy4
Prescribing information
Please see the CIBINQO Summary of Product Characteristics for more information.
Discover the efficacy of CIBINQO
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
I accept and agree to the terms of use.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023